{"success":true,"data":{"pressRelease":{"id":"112328","rtpr_id":"nGNX4y2hxB","ticker":"BSEM","exchange":"OTC","all_tickers":["BSEM"],"title":"BioStem Technologies Announces Nasdaq Uplisting","author":"Globe Newswire","published_at":"2026-08-06T21:38:12.128Z","article_body":"POMPANO BEACH, Fla., Aug. 06, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies\nInc.\n(https://www.globenewswire.com/Tracker?data=FCUi8U6cjftKZN3-m0req7qWYJSOuYn-4PhrS52h2AKqZBjYIqmX4YH2kYEnG3x3z6yXn0ybAHUNXlF4CsXmlhlLSY75jawJjed8CzP2vcEZeQjuhWMEyNw0czP4l3iTJx7J8Ix_INKlTOZY-PiHlcpeQxMS2bLiebpaNvXcpREes0sBr84e38OZbMkaQVTy8p6qMgeI4GiZVWEyUr2bd-peIuQWte8SqAn-k0cgwK6ioPtrd-7djX8OAht_KDWect95Ra9KP0FZCxUIUmmlsYAoRE-Q4OV5yZV3fJcYjbtw26sf2toECKWbxFLyaMGC2Tdr818PR6mDKhnfzyeoX1ZMqN3vaBSVlqrIWnG-S-h_iBIbmMvYJTRp7XGge49KTjIsXdUoMRfSV-Dl7h5DULSfiq811XyxK4t1S9qknUFfOSOGbdp1h_OkNBxdV0d9Jw-w8yxVkLyLaxJB9siwRXQPhjGiGeAfimY_qWWxPelQPPHPfBobDp8B8USPA8a7Nt-F9-TzXr_EUkMmTY5H4fTBy9KFZL5ysZq2LtswheWuL8BYY5VlKNpbeIyFNWsmVuzhzRHZUOKd2GASk8KqGx-ifjuUWI_9-jDZjg4YtfPJxm4cbuKLrR0AT1PBH2YUuL572snCEsnoTmkREqHrbK_GHr9Hmr_tVWrN6buArHyYtt2v_Uu8soc-tBCJdXk-G__5VoesPiUKm8IWIefScHeWyZRFRlLL6bpoqQrES9aXyBL7jw5BN5WWrkSwylIs66ZIrrx3c_D3PwrYM8JtALWc7ID4JQAdlmgBc7LsBH49EcUU17zXfqx_U5ugeNoqbsy9UH7go5wSRoaGRqmnvLe-92REMtaL18xWlLloibaIGURpqpw-qiuoUzOzUR3g_srichgnZ1l4utVHd2EJznu3ZDd5A1nmNNfUKMIKaSlxw2AHcdtd4UFcQt034EAsy4NMVzxLpFtAhs75hA9_pGs-ILtVfBlkHieh2Bhs_nOoj-l1oORJYZNK_uQqgXl9no5kMah7GcDtsuUjcwHbuEfxP90LzZUrXnlEvKA6TQkzWKN5gDlW2UwlIhobQl-lr1aMbvxb7bmna-vxCXS1jKpbxTdO68xSe02xo0BgMDvbDHRGalBFuuik8tfoC4xdHq48kaWOcih6duB8ASIh2cz-1mjCff8VZ65JIMMQEK3bzt3sButreFlbTjfWVwMYaexhf0L90t4KqjPCNI3f0-7q669SiuJ8bwOsojijd3MUIHUPDym3kxLWoOv7oDaF4kjutCsGrKecjnrzDRvsunUV1NYxSxBz1RFmy5lwK4rOofE1RchzyyoPpJFvzM-COjq6PO9rbV2CmDS8UoMxhLf0jleDVDss-YON3IeZH4xOyPu7GdozxDbXX3IUvPtkWvM_MPN6PADUzceFf0tGA0VKHUU4gTQ8Lm1KqHx2bq33r94xUaznuZyEcDzu9FbnLZLq3xwaz2Cl58BARyq2MqJZR84hWVBIb5Mmwe3QnYKvUW3QRR4nTv-PcUNekbnrLYQWQLY819i0RmdF3upxuqJ_4RKY0GXG8DC5ponfPLMABfdRW3mbP97ZPow5VUvfUmzN3R-N3Fz4kI91nyvQaYOjWRh_By-oLlkYhTeOyr3bejYDqRM_M_d8QfW1oUMm)\n(OTC: BSEM) (“BioStem” or the “Company”), a leading regenerative\nmedicine company focused on the development, manufacturing, and\ncommercialization of perinatal tissue allograft products, today announced that\nThe Nasdaq Stock Market LLC (“Nasdaq”) has completed its review of the\nCompany’s listing application and approved the Company’s common stock for\nlisting on The Nasdaq Capital Market. The Company’s common stock is expected\nto begin trading on Nasdaq on August 7, 2026 under the ticker symbol\n“BSEM.”\n\n\"Our uplisting to Nasdaq is an important milestone for BioStem, reflecting the\nsignificant progress we have made in strengthening our foundation,\nstreamlining our operations, and executing on our core business strategy,\"\nsaid Jason Matuszewski, Chairman and CEO of BioStem Technologies. \"We believe\nthis uplisting will expand our access to capital, improve market visibility\nand liquidity for our shareholders, and reinforce our ability to attract\nexceptional talent as we continue to grow. We are deeply grateful to our\npartners, investors, and stakeholders for their continued support throughout\nthis process.\"\n\nShareholders are not required to take any action as a result of the listing,\nand the Company’s ticker symbol “BSEM” will remain unchanged.\n\nAbout BioStem Technologies, Inc. (OTC: BSEM): BioStem Technologies, Inc. is a\npublicly traded, biomedical innovator, focused on developing, manufacturing\nand commercializing advanced allograft solutions derived from perinatal\ntissue. The Company leverages its industry-leading proprietary BioRetain®,\nCryoTek® and SteriTek® processing technologies, designed to optimize the\npreservation of the natural properties of these tissues, supporting their use\nin clinical settings. Its allografts are used by clinicians across a wide\nrange of specialties. With a growing portfolio of products, expanding clinical\nresearch initiatives, and a national commercial footprint, BioStem is\ncommitted to advancing innovation in regenerative medicine.\n\nBioStem Technologies’ quality management system and standard operating\nprocedures have been reviewed and accredited by the American Association of\nTissue Banks (“AATB”). These systems and procedures are established in\ncompliance with current Good Tissue Practices (“cGTP”) and current Good\nManufacturing Practices (“cGMP”). BioStem’s portfolio of quality brands\nincludes its Neox®, Clarix®, VENDAJE® and American Amnion™ product lines.\n\nForward-Looking Statements: Except for statements of historical fact, this\npress release also contains forward-looking statements. These forward-looking\nstatements relate to expectations or forecasts of future events.\nForward-looking statements may be identified using words such as\n“forecast,” “intend,” “seek,” “target,” “anticipate,”\n“believe,” “expect,” “estimate”, “plan,” “outlook,” and\n“project” and other similar expressions that predict or indicate future\nevents or trends or that are not statements of historical matters.\nForward-looking statements in this press release include, without limitation,\nstatements regarding the expected commencement and timing of trading of the\nCompany’s common stock on Nasdaq, the anticipated benefits of the Nasdaq\nuplisting, including expected access to capital, market visibility, trading\nliquidity, the Company’s ability to attract and retain talent, and the\nCompany’s future growth, and the Company’s ability to maintain compliance\nwith Nasdaq’s continued listing standards.\n\nForward-looking statements with respect to strategies, prospects and other\naspects of the business of the Company are based on current expectations that\nare subject to known and unknown risks and uncertainties, which could cause\nactual results or outcomes to differ materially from expectations expressed or\nimplied by such forward-looking statements. These factors include, but are not\nlimited to: the risk that trading of the Company’s common stock on Nasdaq\nmay not commence when expected or at all; the risk that the Company may be\nunable to maintain compliance with Nasdaq’s continued listing standards; the\nrisk that the Nasdaq uplisting does not result in the anticipated benefits,\nincluding expanded access to capital, improved market visibility, increased\ntrading liquidity, or an enhanced ability to attract and retain personnel; the\ncompetition that the Company faces, which could adversely affect its business,\nresults of operations and financial condition; rapid technological change\ncould cause the Company’s products to become obsolete and if the Company\ndoes not enhance its product offerings through its research and development\nefforts, it may be unable to effectively compete; the Company’s ability to\nconvince physicians that its products are safe and effective alternatives to\nexisting treatments and that its products should be used in their procedures;\nthe risk that the Company may be unable to raise funds to expand its business;\nchanges in applicable laws or regulations; the possibility that the Company\nmay be adversely affected by other economic, business, and/or competitive\nfactors; and the other risks and uncertainties described under “Risk\nFactors” in the Company’s Form 10 registration statement and its\nsubsequent filings with the U.S. Securities and Exchange Commission. You are\ncautioned not to place undue reliance upon any forward-looking statements,\nwhich speak only as of the date made. Although it may voluntarily do so from\ntime to time, the Company undertakes no commitment to update or revise the\nforward-looking statements, whether as a result of new information, future\nevents or otherwise, except as required by applicable securities laws.\n\nJoin BioStem’s Distribution List & Social Media:\nTo follow the latest developments at BioStem, sign up for the Company’s\nemail distribution list HERE\n(https://www.globenewswire.com/Tracker?data=FXeFxb-Y935xutIHeBfu2EGiHCydPoTLXiyZ53eo5x2lNzCIB_4VIJlou2HUtBBZbyONBXIZ8XdEw31wkynWX7InVoWx9Lh6-8nZ0nCvuPeEsoU128-Jjud_li2MBAHj_hleyaSCIUo_Fn5FUD62iUZiaXJOuiS3Y19yLZf_S_55tRyZLoLqumjb8b94amjQacQuPLurn4MW6YWAkys7Hi92Vc7OguIhpi4xyaI8pLSG6gEnWAH5PIxdUEDTU4h2pEXAidiZepC90yg84GMntOsg_zWvEMn8zMwBFPf2UZuwHJeVSBik4MNLkASNzLdGDRl4bzcFQqkMuEeX8RkApZ9UcixXN3l1ZSwCKSQiVDXR-KO2Nhv5g4s7Uaz-141UirDbCiyQo2sQUEvtQjLIEfRd7fyaZsYagdJr3VRezpZIj6rxCMJMTz-kaYlMmeDN630TvJIYZkZZnjEFYykD7GcewJJ9AK4FZg2NOwY1OLn5ZPm5B-twxDpdJu76aW_qtDDhb_YqG7X-JMDfha_yyqtw6baoYvYmgaMpB3kopx72FPtmEv8M5BEmrBceKdh41O_DcJqASvGGrNnbvA5ulaTX9Py1kiiOIzw_ALyvWMTHJ_Z3NHGqdUnWsIABAcTWmLcX2JOy_i48slnzfciFwix-buojZLrOtVxDCo8wqHmrWcknPCMv6v078Ug7AYs6pJzvffvVSBYSkq_LKOI_IpI0ey3QvIwtCwOx4nZHOud6zBjqOVa9yZnRpI4LACcatGpNSKUQM0nOuxJV7aGwWWuQAEvvA5wgbX9wV7ayrSXwtuhg9GCzkBVYnba3-OEwSekj6NfysTS5SlU7_3KeEXRGaryiPzWVmTasDATx5sLoyabkpb-ODRwRFKGjsgSHjjloxV_j-jS2yXUVjfldwnA5ZceIKXbWdaYWehkkz66ClZq-AIyuyYp1vy_gsZlkn7uxFzoT-D4KjhfavMgpx_aUXcnb2vNg4RdcY7QOOX6YuZaGf_XQl0qvMRkRl9AwAhLwYA127IedKmQOGGXtYMC6KkcsnCUwH6W_6yIcl-99xD6wRm_YokbbThj3hQwlPSH4750ItJKZ8l2yUTaHUEipQPjx3-V1xZMK-4mAxPeB1A1JjAihWAe6ln0oifPS8jgPhDtV4Nir_2VgQRWNLOU6NvrLEN1OMPqqRC7k33AFC3OTbR9P9nceD8fTqlbAN7S6lCwIAL1V0R9nsgjaS6KoblGMxpKRgnsXPQV_7sDIVztU66KgGyTQiTbTScox_hH1tgW8Wjbtggub7CviufQdzNv-1hA8ecvLPfMqOpWNfsN3ucjir0JzeODwZoOLXIRTMEx4BvH8KQ7SceHWP5VHkW_0rj9NyKXKcTrz_5g=),\nand follow us on X\n(https://www.globenewswire.com/Tracker?data=oN1ew5VgVHnTNeJLMbjtRE5DgnjQ-ZZiyOOzSFhCvCbqYhSQPtOnIdG9vaJXU_kdI9jUivpucD-LtnOw2yyiDRUoQuPk-2ROPPnT2rLTvMOGpubRaKdwLtHr689XXwvAnPKogyOdbhMPqa0ksB94HvQ61KwY7QYRRCVOrO2b91JcPKerJAVOouDTNVVjpwQEiSHTjXeVCLNdDjd7E2NP40YwqlaU6RW9KFHLKeIbpbSvp_nFxXX-6SgpjmuUmIcKJSdU4NL0mfJEZbuRX5tVLBRVuiboMCwCHdiZlttQlAo4d-mKW1-RZMIdXUhyzf3a2PrpQANhu_gKWeF9958pJl7_MYubboA_b0CAxoGauIxzVxHZDkD8Pxzae5St4OPVwUbde3muYnn_zQPLM3EFYam2igEDvJHsNF-HKqDr9fjdJi__fv4N1TiGctcuywhGNEOsovQGPTzKn8iiPGQG53WR5ektSQ-PpWoVqvaTFqSw05JNsmf8VZWGZ11vw4gBr1v_u0Ni1XBHjczgqsRKN1X4RR3CH43kU9wvyhdmIrMZk51MO0fUW6huL1NfgU7Rupv5_b0pGsZbs6IL45PDZNboB27BFo3ZKUHI8KgW2id40Rsun_BuPCD6DescPIBFzm2slZmOAz2XkPZoe32pUY9sa5R5JcIbeH_V_NhRCxT8GRj_u_ZvrRo2TWJRXDoaorCAp7x2-g4ToRSo59yQw1ddXpB60iYQM8kbotdjujdOezD4DRgPok4hxS_y3-s6grCRH8cF5-tSDW2JguhXA1cR0EdF7AzBj1FR9Z7Yo6efmfh9X0uU0JDqEO2Fjo5CpK1FUliOigDHjRycx49rh0Jpo0fkEOvhi_oLpEVEW0QjgwilVXSxshnyBYSwyPFQcpyEmZPj5a6PNbCHaBhBFaUv9ildvjrgnmUW9bKg9IlkfSE_H4rRZhJxr8lbneAtSzssUzN6Ro2b7YwY4LSGVLQNCPvs-sDw6koTKwzu3HfxEEe9muXUK_RfXvXYtI2OIWzIJneaN9dBHRnb4JkZgmyhQC2PCVG_KrjOHxJkpJjT8QUuEJYAzQ6JGQCrzvCJtDkM3QLMQzOM2hmcv2Az4ohMJm1MXhJ8b0eFnoZnv2BRCiq8iWe14K2vu6DVCoP1d9h9Md3YjAT-KlZD4g_EoIcDOQX2Nx4biL4yAXQf3ad4tRostsEZAiKdkV_PbhCEnGA42_8DjDsyGApBRJ2CscGlKGIqrzemYTABfSNY1F16P6sFqQKHE0vV52Bxxpu8XtiNx8ORNxkVUifiiXgovDWNx6RQeIeI3JougRgpIuQaSFDjRoJQRwdExL4afdhfDR5z04ZjnUFsqOaH449TMWuzGSwC-QVrbRohptLLUfcDQvUdvzi_tAImjUpgqM47CM63G-OzhRvZ6pmtnCqV-ouPfKK5qsI3r13RPaamCH3SJtqG7-NvPxfywJJr3aMwIy2pTKGSFmQpPUnnIV6SOn3DanFS2MYyBVcoAT6tqgeNea9qD5pfCUmMc2z0VtadhByKXN0uzeumfOrtD1dwdcJy7LYqKEk2pJJrrfBggdvgJLfgYNihZJMdk02xKjGlFkLY_SWLfP5AlmfTLcnoWVvlOK2s8AqdXE7-n507M2MzdypX9EvBpDAlu455Qyom2zn3FQgKSmThfMguHbb5vqAf-Lm1tgImb4w_CycdiQbqeVkJf51xvajE-Zkguqc-23l9dKfOZtih4OcXQOoJM6u2JUnKQoL0XoA1e2oPYyE=)\nand LinkedIn\n(https://www.globenewswire.com/Tracker?data=Wbay45If12rvAtK7AS1CR_JfqlGGjNcsPAoWMsJxNGeXpqJMgPrFtQknAyOC5Ey10wsDeVUeQApgTv6zPh8wQqVRdDabtijrVSoviGJO4I-QfDI3x-aViq6BSd8kQhPBUimI4WaRgjRQkTeTObMpws7LlHldnNFhYVFfaV19yg-OB2XNH77_IvAH6USe54b8DkAVoVFBOwzNdJPbx41LdswqJ72gejfw-dU1o1J7gDjZYdftwNUVx3lCZou939U692E3GxSVfO4xTQdhgxKLJh7qDJFk7moWC1OI7ilD0Z-6yjHSfhqVkYEyqvVYHXnx619L3yZlzwncr-MDmoDlR6dsW4uL8M3HBp-jO0hPzwhf1R79aqLdqKFbwc8SxPBQTmowcuiCBrCdb9V8VtElbt-CbJUWddrgrfZZrlQpp6nQTFSDuoJtRAVCzTEUWYCezUr1d7YBCmG7nzLsv72gm7RT3XA596UzTvBpJlkKULtFJ6IqncxR7ejcoKns0C2OuPn8bMhNKuMxGv_91F2pk8ync4E3NVwO-lGiA04sabwSoLyN6CetEnP-KgB_TrAh8C_CnlT4E2qv46zvlpXyKtftsuzImja6D9W4hi5Bs3gt7sJH2-UxKDABQ1USSbxkYL55rGz-ZsfZHBsMoLQAD0KgucPLvUkdZlpglIIRC_kojO4Ek6I-AqU74W7A6UHReoc0DprLYujF-21Z-zqSonbVoBtqNLlLcNX-yLPpZ57pHfOCuU73pVvDumA4ycZjhrIsQJo8N697_2-CezQUbQZ1ZYxqZWDYlyZAHM5pPJ38yko_BHkfTFMDtNSmA3zGhAgCR-lkfNtLOixFRZvH19avS6qRfQbcURd-v424z-pLtBzvSWYlKT3wx4Wh_ReCFAYfFtc4OGtpH0OlBNTH607vIbW_MCAs94h-Dgbr8dIUcLLnO7vJSFRSwHM5WRUF6RyZsVzxlSOBjTEvZ5QljMonjs2E0x-IdKW3uPoFhN6EPmUe8VUqhrFXwvmxWScVdph5ANdDwEPz5bFAdDX8kuq3ou6_6ononXrkfEMeh0ik-gPJFA4X3nGnw84Qnu_UhIAEZr9xmhUvskf0zB2aRWsm1zNn9EDEqYxqxI6rlOEJjG4DDYcfw6zQuUxkrMjZZk0BsAs5PAFk03LD_zIdCi7fOdrWGfIpgZhWshaPw2W_U0t2yU5IOHKoX2Sp9qwApr8ufqMyn3QXh6j-U7Qp44TpJw_NnjwGXnZ4Zfb58j_QJS-AYpI6fY8ejCN-G5HlaqOtcpILTbDWSTtjlf8zyeVvMkjE955pdL8agH-v2ILYNaZgydx_SSkuEsboPzzKI-MnSJboL7ooBnO-PoXiiCK6W9gApQxmhS9iAous6Ity1K5rW5xEYbUO5eqQfRMwEdjU3s6io1izin14mXbrCHAM2XJ-XbFzoZxlz040w0T1QdaPJt9EJ4TOqyMop6L77mq_n5g-oG5GhulgwtFjz6nTpbDdpEFx5aZKzI9E31621Um0qT0ruqO-_cLTwQycabI5XuYaCW7wv4s7V7t_xkhcgBBFxzMcZ24MnWwqRAsttWszap_YRyFKZSyk0pHr6oIaCx-p_itJPur4tty6JFZrnZlTvbjSljGWRj6XYM3bTw-1kE52AT0BhoPNFuj9HEoCjHIyQ7cbKKOPHd2nBoGMgqhqpTsBTW3K6qv-o63_NLEBtJHHF-b0YNu33ldoMthpN3-on-UAYPCR2-CyEOUOI1K_fEv6mIEMIolr8Gw=).\n\nContact BioStem:\nWebsite: www.biostemtechnologies.com\n\n(https://www.globenewswire.com/Tracker?data=IfVQHBcDl3fQVzLgKkaH0e0uNcoadjjt932cR0CGH8hevu9yRtocqwyCGcrkbK-4PfIhicn4Q54DRZmkt3urLKGsJai2PAo9l_ZVFq1xrna3a4emLpNvbVA9OOmbiY8xr1_ujKOKJFQEUO1VSBRkLME5AbTxDTg73aM_-UimF-ntprxTz-11QUPrqw5k4rhqhfo6j0VxxS1lyTYiTtbPSRCt2dp8uxA1IVn4li6eA6VDrOlit8W6tNQSb5Bw3DAWlqqyXakd98TtLwBL3RpFwNRUXuadOFLIJ8zWNSmdYBqAzIyl0QvuV_ezWLqbbnAuAxHjj2nT7hPlQONGk5kbjn0CV9-yfomaf50JBq1DgdyQHmjQw3DsaJfhzt-CGh5S)E-Mail:\npr@biostemtech.com\n\n(https://www.globenewswire.com/Tracker?data=PCLIIO0ymodSWUyzqNlz6qR3vIzzSHlHc8IWYbzTu0FCu_zDrTTlmhHBNa08QYF2DJhkjFBicy5jjJJgGdKLQQ==)X:\n@BSEM_Tech\n\n(https://www.globenewswire.com/Tracker?data=3pLV7Wu7SMOnWi-FFfubGtRWFlJvhMNH-3wTgqBnyCZZ5EH57cNrZjBXeG2ZkdUs8mA4qnjem-uY9YyCqtGXyLumJB_OBemv4rnsJDGiIF9PfKAABeSXhM0eM3U9yY3RO9oovMK0ZFIoHwbgQWEAlBVkX9y9uo7UgvRLXPhYmU-QEJxCQg_lGUHnM33POIaiOSaJ9nPUkW6q0WDorf9i_yjhgyBMIT8s7j2ceOOQDbWNM_mIpwPJoIPz0Ip7ZPdJMyCe5C4XVCs4FWWmKeJnjyu3uiX4Qr2rLjHPPu_oYQLfoRxx0tY7OaEWIR4iOdJbVMp4QAq0rJch8ZtgoAL2rh0G3BF7ZafvXnIvqaFznVWTiHR2t8rEkpaB2Xbv7b-_fAJPiWQN3g58OpQfTa283erhwQkWgUAJ-39JIT-NzB1g5YHzJL60rK2-UEr7PWFfsE9N7WVVE_9pcq4TaWfxJIGhQ580LDxcqGN_FybqycQHxQm13QPTazXWKjl8utNRbir4IYYiqoPy6_S81ecIu8XxOK6L6bMzwjnT0okm3agCtBMY9zzwFQHm5xP0eBIWLvG7Mkq-Lbn6_YuvYGgKVIMuvQMoDsk_aWH9_PKUQRdj--03ZQR9vGvs3u5JIY4gNB4rUsVp2cRdw5Qdbc0JXDHyEEOm3OoHASEuU_3G9OkwBr8dn3JDDbSV3755a_6CT-cU2j-TuO3F1fc55GWph19LVh2xeg7GKCP80NBPwtk8QUm-N-kUw6qBuDrzTt1Yaf4UTgxa3ZxkUG4Q5_F1zlLAx_1qYM4W9url2iGlpQiRu1DIYPNCNKcirk5jm4PxnUT-NFxShWqdd6VnAurRoeHEPhf1ajloe_gMrEjrbWIAJYUr4UphQk8iVoii9tFDhTrI6bDGuKFIp-jcMBxNlYvdoKOhpymCbltuAdQNNZ2h1QaT9srhLfyKAf5F6-NLN3TeJ1lanMJHgKAS8rDHE5MxO-0Mu3Loim1Zsg_Ub7kdVhl5uVPJb9uUIof59emAlInfXuNawq07I6B8wg0d8B5DKtl6nrIW2JzsqqTzxF0B3eaL0sMwUwYDbliQBECIlwwMDE-KmlJzmUs-5VMyBh87FtjSh0AS_RGSyiAIla3GgyrdAREkQRLioUcwLLrjJmLEVWsxovDDz-SlQIykAefI4jIeP_f1a2z2yWZobM9NoEVbP7VRgczHFYr8HrhrV-R2S8ZP0jNgKrBhIfnIVsCujlXxoSCUNeTxhOQ7VYa6s-aZVq9rM3tiRXEAI45LPJpqbdtJczY7jEO1IZoZEw==)Facebook:\nBioStemTechnologies\n(https://www.globenewswire.com/Tracker?data=FCUi8U6cjftKZN3-m0req20eREQVUBRVtcvvD8bRvXMrbtf2nZ0rcc3vkjd9q0lXCUKsA2xGzWwGemjmRt8IP7LwjBIuo2RNQsbbUw_hOZgIloBOJkftxlAldTahmxyVlRbCHUnbHD-D9nAOfebRwm6NErcLCyS_3vYoqga3QI6qx_QqHpcFgNvFeu87bm3LeXJ07EKbzI2fWKpw8Meb1ePQKi_EXwlpGXo2qbiUO-vWGGIHPq7qqrqDiAtnZEWc6Z6ZI_jT0GrDzCoJ8uw-GaUqvsWIYZ4IyFpJyZeaSTF4wfbJyWHLTP76q0y4v3wY6AhjWQwD4wPGgHSKqPNnrjatcHRfSpJV6q-moECczqVOwaTOAogJgcRKZBsIZMqzbKVr4JQ3eqhNk_nQV80fhZcNF3X2HLt3j6bDpAeHcYc=)\nPhone: 954-380-8342\n\nInvestor Relations:\nPhilip Trip Taylor, Gilmartin \nir@biostemtech.com\n\nPublic Relations:\nJennifer Horton, Relevance\njennifer@relevance.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/da0ea21a-fd6e-425a-a8f2-6f69dc2b4612)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX4y2hxB","title":"BioStem Technologies Announces Nasdaq Uplisting","author":"Globe Newswire","ticker":"BSEM","created":"2026-08-06T21:38:12.128Z","tickers":["BSEM"],"exchange":"OTC","article_body":"POMPANO BEACH, Fla., Aug. 06, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies\nInc.\n(https://www.globenewswire.com/Tracker?data=FCUi8U6cjftKZN3-m0req7qWYJSOuYn-4PhrS52h2AKqZBjYIqmX4YH2kYEnG3x3z6yXn0ybAHUNXlF4CsXmlhlLSY75jawJjed8CzP2vcEZeQjuhWMEyNw0czP4l3iTJx7J8Ix_INKlTOZY-PiHlcpeQxMS2bLiebpaNvXcpREes0sBr84e38OZbMkaQVTy8p6qMgeI4GiZVWEyUr2bd-peIuQWte8SqAn-k0cgwK6ioPtrd-7djX8OAht_KDWect95Ra9KP0FZCxUIUmmlsYAoRE-Q4OV5yZV3fJcYjbtw26sf2toECKWbxFLyaMGC2Tdr818PR6mDKhnfzyeoX1ZMqN3vaBSVlqrIWnG-S-h_iBIbmMvYJTRp7XGge49KTjIsXdUoMRfSV-Dl7h5DULSfiq811XyxK4t1S9qknUFfOSOGbdp1h_OkNBxdV0d9Jw-w8yxVkLyLaxJB9siwRXQPhjGiGeAfimY_qWWxPelQPPHPfBobDp8B8USPA8a7Nt-F9-TzXr_EUkMmTY5H4fTBy9KFZL5ysZq2LtswheWuL8BYY5VlKNpbeIyFNWsmVuzhzRHZUOKd2GASk8KqGx-ifjuUWI_9-jDZjg4YtfPJxm4cbuKLrR0AT1PBH2YUuL572snCEsnoTmkREqHrbK_GHr9Hmr_tVWrN6buArHyYtt2v_Uu8soc-tBCJdXk-G__5VoesPiUKm8IWIefScHeWyZRFRlLL6bpoqQrES9aXyBL7jw5BN5WWrkSwylIs66ZIrrx3c_D3PwrYM8JtALWc7ID4JQAdlmgBc7LsBH49EcUU17zXfqx_U5ugeNoqbsy9UH7go5wSRoaGRqmnvLe-92REMtaL18xWlLloibaIGURpqpw-qiuoUzOzUR3g_srichgnZ1l4utVHd2EJznu3ZDd5A1nmNNfUKMIKaSlxw2AHcdtd4UFcQt034EAsy4NMVzxLpFtAhs75hA9_pGs-ILtVfBlkHieh2Bhs_nOoj-l1oORJYZNK_uQqgXl9no5kMah7GcDtsuUjcwHbuEfxP90LzZUrXnlEvKA6TQkzWKN5gDlW2UwlIhobQl-lr1aMbvxb7bmna-vxCXS1jKpbxTdO68xSe02xo0BgMDvbDHRGalBFuuik8tfoC4xdHq48kaWOcih6duB8ASIh2cz-1mjCff8VZ65JIMMQEK3bzt3sButreFlbTjfWVwMYaexhf0L90t4KqjPCNI3f0-7q669SiuJ8bwOsojijd3MUIHUPDym3kxLWoOv7oDaF4kjutCsGrKecjnrzDRvsunUV1NYxSxBz1RFmy5lwK4rOofE1RchzyyoPpJFvzM-COjq6PO9rbV2CmDS8UoMxhLf0jleDVDss-YON3IeZH4xOyPu7GdozxDbXX3IUvPtkWvM_MPN6PADUzceFf0tGA0VKHUU4gTQ8Lm1KqHx2bq33r94xUaznuZyEcDzu9FbnLZLq3xwaz2Cl58BARyq2MqJZR84hWVBIb5Mmwe3QnYKvUW3QRR4nTv-PcUNekbnrLYQWQLY819i0RmdF3upxuqJ_4RKY0GXG8DC5ponfPLMABfdRW3mbP97ZPow5VUvfUmzN3R-N3Fz4kI91nyvQaYOjWRh_By-oLlkYhTeOyr3bejYDqRM_M_d8QfW1oUMm)\n(OTC: BSEM) (“BioStem” or the “Company”), a leading regenerative\nmedicine company focused on the development, manufacturing, and\ncommercialization of perinatal tissue allograft products, today announced that\nThe Nasdaq Stock Market LLC (“Nasdaq”) has completed its review of the\nCompany’s listing application and approved the Company’s common stock for\nlisting on The Nasdaq Capital Market. The Company’s common stock is expected\nto begin trading on Nasdaq on August 7, 2026 under the ticker symbol\n“BSEM.”\n\n\"Our uplisting to Nasdaq is an important milestone for BioStem, reflecting the\nsignificant progress we have made in strengthening our foundation,\nstreamlining our operations, and executing on our core business strategy,\"\nsaid Jason Matuszewski, Chairman and CEO of BioStem Technologies. \"We believe\nthis uplisting will expand our access to capital, improve market visibility\nand liquidity for our shareholders, and reinforce our ability to attract\nexceptional talent as we continue to grow. We are deeply grateful to our\npartners, investors, and stakeholders for their continued support throughout\nthis process.\"\n\nShareholders are not required to take any action as a result of the listing,\nand the Company’s ticker symbol “BSEM” will remain unchanged.\n\nAbout BioStem Technologies, Inc. (OTC: BSEM): BioStem Technologies, Inc. is a\npublicly traded, biomedical innovator, focused on developing, manufacturing\nand commercializing advanced allograft solutions derived from perinatal\ntissue. The Company leverages its industry-leading proprietary BioRetain®,\nCryoTek® and SteriTek® processing technologies, designed to optimize the\npreservation of the natural properties of these tissues, supporting their use\nin clinical settings. Its allografts are used by clinicians across a wide\nrange of specialties. With a growing portfolio of products, expanding clinical\nresearch initiatives, and a national commercial footprint, BioStem is\ncommitted to advancing innovation in regenerative medicine.\n\nBioStem Technologies’ quality management system and standard operating\nprocedures have been reviewed and accredited by the American Association of\nTissue Banks (“AATB”). These systems and procedures are established in\ncompliance with current Good Tissue Practices (“cGTP”) and current Good\nManufacturing Practices (“cGMP”). BioStem’s portfolio of quality brands\nincludes its Neox®, Clarix®, VENDAJE® and American Amnion™ product lines.\n\nForward-Looking Statements: Except for statements of historical fact, this\npress release also contains forward-looking statements. These forward-looking\nstatements relate to expectations or forecasts of future events.\nForward-looking statements may be identified using words such as\n“forecast,” “intend,” “seek,” “target,” “anticipate,”\n“believe,” “expect,” “estimate”, “plan,” “outlook,” and\n“project” and other similar expressions that predict or indicate future\nevents or trends or that are not statements of historical matters.\nForward-looking statements in this press release include, without limitation,\nstatements regarding the expected commencement and timing of trading of the\nCompany’s common stock on Nasdaq, the anticipated benefits of the Nasdaq\nuplisting, including expected access to capital, market visibility, trading\nliquidity, the Company’s ability to attract and retain talent, and the\nCompany’s future growth, and the Company’s ability to maintain compliance\nwith Nasdaq’s continued listing standards.\n\nForward-looking statements with respect to strategies, prospects and other\naspects of the business of the Company are based on current expectations that\nare subject to known and unknown risks and uncertainties, which could cause\nactual results or outcomes to differ materially from expectations expressed or\nimplied by such forward-looking statements. These factors include, but are not\nlimited to: the risk that trading of the Company’s common stock on Nasdaq\nmay not commence when expected or at all; the risk that the Company may be\nunable to maintain compliance with Nasdaq’s continued listing standards; the\nrisk that the Nasdaq uplisting does not result in the anticipated benefits,\nincluding expanded access to capital, improved market visibility, increased\ntrading liquidity, or an enhanced ability to attract and retain personnel; the\ncompetition that the Company faces, which could adversely affect its business,\nresults of operations and financial condition; rapid technological change\ncould cause the Company’s products to become obsolete and if the Company\ndoes not enhance its product offerings through its research and development\nefforts, it may be unable to effectively compete; the Company’s ability to\nconvince physicians that its products are safe and effective alternatives to\nexisting treatments and that its products should be used in their procedures;\nthe risk that the Company may be unable to raise funds to expand its business;\nchanges in applicable laws or regulations; the possibility that the Company\nmay be adversely affected by other economic, business, and/or competitive\nfactors; and the other risks and uncertainties described under “Risk\nFactors” in the Company’s Form 10 registration statement and its\nsubsequent filings with the U.S. Securities and Exchange Commission. You are\ncautioned not to place undue reliance upon any forward-looking statements,\nwhich speak only as of the date made. Although it may voluntarily do so from\ntime to time, the Company undertakes no commitment to update or revise the\nforward-looking statements, whether as a result of new information, future\nevents or otherwise, except as required by applicable securities laws.\n\nJoin BioStem’s Distribution List & Social Media:\nTo follow the latest developments at BioStem, sign up for the Company’s\nemail distribution list HERE\n(https://www.globenewswire.com/Tracker?data=FXeFxb-Y935xutIHeBfu2EGiHCydPoTLXiyZ53eo5x2lNzCIB_4VIJlou2HUtBBZbyONBXIZ8XdEw31wkynWX7InVoWx9Lh6-8nZ0nCvuPeEsoU128-Jjud_li2MBAHj_hleyaSCIUo_Fn5FUD62iUZiaXJOuiS3Y19yLZf_S_55tRyZLoLqumjb8b94amjQacQuPLurn4MW6YWAkys7Hi92Vc7OguIhpi4xyaI8pLSG6gEnWAH5PIxdUEDTU4h2pEXAidiZepC90yg84GMntOsg_zWvEMn8zMwBFPf2UZuwHJeVSBik4MNLkASNzLdGDRl4bzcFQqkMuEeX8RkApZ9UcixXN3l1ZSwCKSQiVDXR-KO2Nhv5g4s7Uaz-141UirDbCiyQo2sQUEvtQjLIEfRd7fyaZsYagdJr3VRezpZIj6rxCMJMTz-kaYlMmeDN630TvJIYZkZZnjEFYykD7GcewJJ9AK4FZg2NOwY1OLn5ZPm5B-twxDpdJu76aW_qtDDhb_YqG7X-JMDfha_yyqtw6baoYvYmgaMpB3kopx72FPtmEv8M5BEmrBceKdh41O_DcJqASvGGrNnbvA5ulaTX9Py1kiiOIzw_ALyvWMTHJ_Z3NHGqdUnWsIABAcTWmLcX2JOy_i48slnzfciFwix-buojZLrOtVxDCo8wqHmrWcknPCMv6v078Ug7AYs6pJzvffvVSBYSkq_LKOI_IpI0ey3QvIwtCwOx4nZHOud6zBjqOVa9yZnRpI4LACcatGpNSKUQM0nOuxJV7aGwWWuQAEvvA5wgbX9wV7ayrSXwtuhg9GCzkBVYnba3-OEwSekj6NfysTS5SlU7_3KeEXRGaryiPzWVmTasDATx5sLoyabkpb-ODRwRFKGjsgSHjjloxV_j-jS2yXUVjfldwnA5ZceIKXbWdaYWehkkz66ClZq-AIyuyYp1vy_gsZlkn7uxFzoT-D4KjhfavMgpx_aUXcnb2vNg4RdcY7QOOX6YuZaGf_XQl0qvMRkRl9AwAhLwYA127IedKmQOGGXtYMC6KkcsnCUwH6W_6yIcl-99xD6wRm_YokbbThj3hQwlPSH4750ItJKZ8l2yUTaHUEipQPjx3-V1xZMK-4mAxPeB1A1JjAihWAe6ln0oifPS8jgPhDtV4Nir_2VgQRWNLOU6NvrLEN1OMPqqRC7k33AFC3OTbR9P9nceD8fTqlbAN7S6lCwIAL1V0R9nsgjaS6KoblGMxpKRgnsXPQV_7sDIVztU66KgGyTQiTbTScox_hH1tgW8Wjbtggub7CviufQdzNv-1hA8ecvLPfMqOpWNfsN3ucjir0JzeODwZoOLXIRTMEx4BvH8KQ7SceHWP5VHkW_0rj9NyKXKcTrz_5g=),\nand follow us on X\n(https://www.globenewswire.com/Tracker?data=oN1ew5VgVHnTNeJLMbjtRE5DgnjQ-ZZiyOOzSFhCvCbqYhSQPtOnIdG9vaJXU_kdI9jUivpucD-LtnOw2yyiDRUoQuPk-2ROPPnT2rLTvMOGpubRaKdwLtHr689XXwvAnPKogyOdbhMPqa0ksB94HvQ61KwY7QYRRCVOrO2b91JcPKerJAVOouDTNVVjpwQEiSHTjXeVCLNdDjd7E2NP40YwqlaU6RW9KFHLKeIbpbSvp_nFxXX-6SgpjmuUmIcKJSdU4NL0mfJEZbuRX5tVLBRVuiboMCwCHdiZlttQlAo4d-mKW1-RZMIdXUhyzf3a2PrpQANhu_gKWeF9958pJl7_MYubboA_b0CAxoGauIxzVxHZDkD8Pxzae5St4OPVwUbde3muYnn_zQPLM3EFYam2igEDvJHsNF-HKqDr9fjdJi__fv4N1TiGctcuywhGNEOsovQGPTzKn8iiPGQG53WR5ektSQ-PpWoVqvaTFqSw05JNsmf8VZWGZ11vw4gBr1v_u0Ni1XBHjczgqsRKN1X4RR3CH43kU9wvyhdmIrMZk51MO0fUW6huL1NfgU7Rupv5_b0pGsZbs6IL45PDZNboB27BFo3ZKUHI8KgW2id40Rsun_BuPCD6DescPIBFzm2slZmOAz2XkPZoe32pUY9sa5R5JcIbeH_V_NhRCxT8GRj_u_ZvrRo2TWJRXDoaorCAp7x2-g4ToRSo59yQw1ddXpB60iYQM8kbotdjujdOezD4DRgPok4hxS_y3-s6grCRH8cF5-tSDW2JguhXA1cR0EdF7AzBj1FR9Z7Yo6efmfh9X0uU0JDqEO2Fjo5CpK1FUliOigDHjRycx49rh0Jpo0fkEOvhi_oLpEVEW0QjgwilVXSxshnyBYSwyPFQcpyEmZPj5a6PNbCHaBhBFaUv9ildvjrgnmUW9bKg9IlkfSE_H4rRZhJxr8lbneAtSzssUzN6Ro2b7YwY4LSGVLQNCPvs-sDw6koTKwzu3HfxEEe9muXUK_RfXvXYtI2OIWzIJneaN9dBHRnb4JkZgmyhQC2PCVG_KrjOHxJkpJjT8QUuEJYAzQ6JGQCrzvCJtDkM3QLMQzOM2hmcv2Az4ohMJm1MXhJ8b0eFnoZnv2BRCiq8iWe14K2vu6DVCoP1d9h9Md3YjAT-KlZD4g_EoIcDOQX2Nx4biL4yAXQf3ad4tRostsEZAiKdkV_PbhCEnGA42_8DjDsyGApBRJ2CscGlKGIqrzemYTABfSNY1F16P6sFqQKHE0vV52Bxxpu8XtiNx8ORNxkVUifiiXgovDWNx6RQeIeI3JougRgpIuQaSFDjRoJQRwdExL4afdhfDR5z04ZjnUFsqOaH449TMWuzGSwC-QVrbRohptLLUfcDQvUdvzi_tAImjUpgqM47CM63G-OzhRvZ6pmtnCqV-ouPfKK5qsI3r13RPaamCH3SJtqG7-NvPxfywJJr3aMwIy2pTKGSFmQpPUnnIV6SOn3DanFS2MYyBVcoAT6tqgeNea9qD5pfCUmMc2z0VtadhByKXN0uzeumfOrtD1dwdcJy7LYqKEk2pJJrrfBggdvgJLfgYNihZJMdk02xKjGlFkLY_SWLfP5AlmfTLcnoWVvlOK2s8AqdXE7-n507M2MzdypX9EvBpDAlu455Qyom2zn3FQgKSmThfMguHbb5vqAf-Lm1tgImb4w_CycdiQbqeVkJf51xvajE-Zkguqc-23l9dKfOZtih4OcXQOoJM6u2JUnKQoL0XoA1e2oPYyE=)\nand LinkedIn\n(https://www.globenewswire.com/Tracker?data=Wbay45If12rvAtK7AS1CR_JfqlGGjNcsPAoWMsJxNGeXpqJMgPrFtQknAyOC5Ey10wsDeVUeQApgTv6zPh8wQqVRdDabtijrVSoviGJO4I-QfDI3x-aViq6BSd8kQhPBUimI4WaRgjRQkTeTObMpws7LlHldnNFhYVFfaV19yg-OB2XNH77_IvAH6USe54b8DkAVoVFBOwzNdJPbx41LdswqJ72gejfw-dU1o1J7gDjZYdftwNUVx3lCZou939U692E3GxSVfO4xTQdhgxKLJh7qDJFk7moWC1OI7ilD0Z-6yjHSfhqVkYEyqvVYHXnx619L3yZlzwncr-MDmoDlR6dsW4uL8M3HBp-jO0hPzwhf1R79aqLdqKFbwc8SxPBQTmowcuiCBrCdb9V8VtElbt-CbJUWddrgrfZZrlQpp6nQTFSDuoJtRAVCzTEUWYCezUr1d7YBCmG7nzLsv72gm7RT3XA596UzTvBpJlkKULtFJ6IqncxR7ejcoKns0C2OuPn8bMhNKuMxGv_91F2pk8ync4E3NVwO-lGiA04sabwSoLyN6CetEnP-KgB_TrAh8C_CnlT4E2qv46zvlpXyKtftsuzImja6D9W4hi5Bs3gt7sJH2-UxKDABQ1USSbxkYL55rGz-ZsfZHBsMoLQAD0KgucPLvUkdZlpglIIRC_kojO4Ek6I-AqU74W7A6UHReoc0DprLYujF-21Z-zqSonbVoBtqNLlLcNX-yLPpZ57pHfOCuU73pVvDumA4ycZjhrIsQJo8N697_2-CezQUbQZ1ZYxqZWDYlyZAHM5pPJ38yko_BHkfTFMDtNSmA3zGhAgCR-lkfNtLOixFRZvH19avS6qRfQbcURd-v424z-pLtBzvSWYlKT3wx4Wh_ReCFAYfFtc4OGtpH0OlBNTH607vIbW_MCAs94h-Dgbr8dIUcLLnO7vJSFRSwHM5WRUF6RyZsVzxlSOBjTEvZ5QljMonjs2E0x-IdKW3uPoFhN6EPmUe8VUqhrFXwvmxWScVdph5ANdDwEPz5bFAdDX8kuq3ou6_6ononXrkfEMeh0ik-gPJFA4X3nGnw84Qnu_UhIAEZr9xmhUvskf0zB2aRWsm1zNn9EDEqYxqxI6rlOEJjG4DDYcfw6zQuUxkrMjZZk0BsAs5PAFk03LD_zIdCi7fOdrWGfIpgZhWshaPw2W_U0t2yU5IOHKoX2Sp9qwApr8ufqMyn3QXh6j-U7Qp44TpJw_NnjwGXnZ4Zfb58j_QJS-AYpI6fY8ejCN-G5HlaqOtcpILTbDWSTtjlf8zyeVvMkjE955pdL8agH-v2ILYNaZgydx_SSkuEsboPzzKI-MnSJboL7ooBnO-PoXiiCK6W9gApQxmhS9iAous6Ity1K5rW5xEYbUO5eqQfRMwEdjU3s6io1izin14mXbrCHAM2XJ-XbFzoZxlz040w0T1QdaPJt9EJ4TOqyMop6L77mq_n5g-oG5GhulgwtFjz6nTpbDdpEFx5aZKzI9E31621Um0qT0ruqO-_cLTwQycabI5XuYaCW7wv4s7V7t_xkhcgBBFxzMcZ24MnWwqRAsttWszap_YRyFKZSyk0pHr6oIaCx-p_itJPur4tty6JFZrnZlTvbjSljGWRj6XYM3bTw-1kE52AT0BhoPNFuj9HEoCjHIyQ7cbKKOPHd2nBoGMgqhqpTsBTW3K6qv-o63_NLEBtJHHF-b0YNu33ldoMthpN3-on-UAYPCR2-CyEOUOI1K_fEv6mIEMIolr8Gw=).\n\nContact BioStem:\nWebsite: www.biostemtechnologies.com\n\n(https://www.globenewswire.com/Tracker?data=IfVQHBcDl3fQVzLgKkaH0e0uNcoadjjt932cR0CGH8hevu9yRtocqwyCGcrkbK-4PfIhicn4Q54DRZmkt3urLKGsJai2PAo9l_ZVFq1xrna3a4emLpNvbVA9OOmbiY8xr1_ujKOKJFQEUO1VSBRkLME5AbTxDTg73aM_-UimF-ntprxTz-11QUPrqw5k4rhqhfo6j0VxxS1lyTYiTtbPSRCt2dp8uxA1IVn4li6eA6VDrOlit8W6tNQSb5Bw3DAWlqqyXakd98TtLwBL3RpFwNRUXuadOFLIJ8zWNSmdYBqAzIyl0QvuV_ezWLqbbnAuAxHjj2nT7hPlQONGk5kbjn0CV9-yfomaf50JBq1DgdyQHmjQw3DsaJfhzt-CGh5S)E-Mail:\npr@biostemtech.com\n\n(https://www.globenewswire.com/Tracker?data=PCLIIO0ymodSWUyzqNlz6qR3vIzzSHlHc8IWYbzTu0FCu_zDrTTlmhHBNa08QYF2DJhkjFBicy5jjJJgGdKLQQ==)X:\n@BSEM_Tech\n\n(https://www.globenewswire.com/Tracker?data=3pLV7Wu7SMOnWi-FFfubGtRWFlJvhMNH-3wTgqBnyCZZ5EH57cNrZjBXeG2ZkdUs8mA4qnjem-uY9YyCqtGXyLumJB_OBemv4rnsJDGiIF9PfKAABeSXhM0eM3U9yY3RO9oovMK0ZFIoHwbgQWEAlBVkX9y9uo7UgvRLXPhYmU-QEJxCQg_lGUHnM33POIaiOSaJ9nPUkW6q0WDorf9i_yjhgyBMIT8s7j2ceOOQDbWNM_mIpwPJoIPz0Ip7ZPdJMyCe5C4XVCs4FWWmKeJnjyu3uiX4Qr2rLjHPPu_oYQLfoRxx0tY7OaEWIR4iOdJbVMp4QAq0rJch8ZtgoAL2rh0G3BF7ZafvXnIvqaFznVWTiHR2t8rEkpaB2Xbv7b-_fAJPiWQN3g58OpQfTa283erhwQkWgUAJ-39JIT-NzB1g5YHzJL60rK2-UEr7PWFfsE9N7WVVE_9pcq4TaWfxJIGhQ580LDxcqGN_FybqycQHxQm13QPTazXWKjl8utNRbir4IYYiqoPy6_S81ecIu8XxOK6L6bMzwjnT0okm3agCtBMY9zzwFQHm5xP0eBIWLvG7Mkq-Lbn6_YuvYGgKVIMuvQMoDsk_aWH9_PKUQRdj--03ZQR9vGvs3u5JIY4gNB4rUsVp2cRdw5Qdbc0JXDHyEEOm3OoHASEuU_3G9OkwBr8dn3JDDbSV3755a_6CT-cU2j-TuO3F1fc55GWph19LVh2xeg7GKCP80NBPwtk8QUm-N-kUw6qBuDrzTt1Yaf4UTgxa3ZxkUG4Q5_F1zlLAx_1qYM4W9url2iGlpQiRu1DIYPNCNKcirk5jm4PxnUT-NFxShWqdd6VnAurRoeHEPhf1ajloe_gMrEjrbWIAJYUr4UphQk8iVoii9tFDhTrI6bDGuKFIp-jcMBxNlYvdoKOhpymCbltuAdQNNZ2h1QaT9srhLfyKAf5F6-NLN3TeJ1lanMJHgKAS8rDHE5MxO-0Mu3Loim1Zsg_Ub7kdVhl5uVPJb9uUIof59emAlInfXuNawq07I6B8wg0d8B5DKtl6nrIW2JzsqqTzxF0B3eaL0sMwUwYDbliQBECIlwwMDE-KmlJzmUs-5VMyBh87FtjSh0AS_RGSyiAIla3GgyrdAREkQRLioUcwLLrjJmLEVWsxovDDz-SlQIykAefI4jIeP_f1a2z2yWZobM9NoEVbP7VRgczHFYr8HrhrV-R2S8ZP0jNgKrBhIfnIVsCujlXxoSCUNeTxhOQ7VYa6s-aZVq9rM3tiRXEAI45LPJpqbdtJczY7jEO1IZoZEw==)Facebook:\nBioStemTechnologies\n(https://www.globenewswire.com/Tracker?data=FCUi8U6cjftKZN3-m0req20eREQVUBRVtcvvD8bRvXMrbtf2nZ0rcc3vkjd9q0lXCUKsA2xGzWwGemjmRt8IP7LwjBIuo2RNQsbbUw_hOZgIloBOJkftxlAldTahmxyVlRbCHUnbHD-D9nAOfebRwm6NErcLCyS_3vYoqga3QI6qx_QqHpcFgNvFeu87bm3LeXJ07EKbzI2fWKpw8Meb1ePQKi_EXwlpGXo2qbiUO-vWGGIHPq7qqrqDiAtnZEWc6Z6ZI_jT0GrDzCoJ8uw-GaUqvsWIYZ4IyFpJyZeaSTF4wfbJyWHLTP76q0y4v3wY6AhjWQwD4wPGgHSKqPNnrjatcHRfSpJV6q-moECczqVOwaTOAogJgcRKZBsIZMqzbKVr4JQ3eqhNk_nQV80fhZcNF3X2HLt3j6bDpAeHcYc=)\nPhone: 954-380-8342\n\nInvestor Relations:\nPhilip Trip Taylor, Gilmartin \nir@biostemtech.com\n\nPublic Relations:\nJennifer Horton, Relevance\njennifer@relevance.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/da0ea21a-fd6e-425a-a8f2-6f69dc2b4612)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-08-06T21:38:12.180224229Z","server_sent_at_ms":1786052292180},"received_at":"2026-08-06T21:38:12.330Z","source_url":"https://www.globenewswire.com/news-release/2026/08/06/3340867/0/en/biostem-technologies-announces-nasdaq-uplisting.html"},"analysis":{"id":"101331","press_release_id":"112328","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"operations_update","narrative":"BioStem Technologies announced that its common stock has been approved for listing on the Nasdaq Capital Market, with trading expected to begin on August 7, 2026 under the symbol BSEM.\n\nCEO Jason Matuszewski stated the uplisting reflects progress in strengthening the company's foundation and executing its core strategy, while potentially expanding access to capital and improving market visibility.\n\nThe company is a regenerative medicine firm focused on perinatal tissue allograft products, utilizing proprietary processing technologies such as BioRetain, CryoTek, and SteriTek.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Graduation to Nasdaq marks a key liquidity and visibility milestone for BioStem's regenerative medicine platform."},"keyFigures":null,"quotedText":"Our uplisting to Nasdaq is an important milestone for BioStem, reflecting the significant progress we have made in strengthening our foundation, streamlining our operations, and executing on our core business strategy,","namedEntities":{"people":[{"name":"Jason Matuszewski","role":"Chairman and CEO"},{"name":"Philip Trip Taylor","role":"Investor Relations Contact"},{"name":"Jennifer Horton","role":"Public Relations Contact"}],"products":["BioRetain","CryoTek","SteriTek","Neox","Clarix","VENDAJE","American Amnion"],"companies":[{"name":"BioStem Technologies, Inc.","ticker":"BSEM"},{"name":"The Nasdaq Stock Market LLC","relationship":"exchange"},{"name":"American Association of Tissue Banks","relationship":"accreditation body"},{"name":"Gilmartin","relationship":"investor relations firm"},{"name":"Relevance","relationship":"public relations firm"}],"dollarAmounts":[]},"materialImpact":{"score":3,"reasoning":"Uplisting from OTC to Nasdaq Capital Market is a significant milestone that generally improves liquidity and visibility, though not a binary event like FDA approval or M&A."},"tickerRelevance":{"others":[],"primary":"BSEM"},"globalImportance":15,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"exchange-uplisting"}},"event_type":"operations_update","event_type_secondary":null,"sentiment":"bullish","material_impact_score":3,"narrative":"BioStem Technologies announced that its common stock has been approved for listing on the Nasdaq Capital Market, with trading expected to begin on August 7, 2026 under the symbol BSEM.\n\nCEO Jason Matuszewski stated the uplisting reflects progress in strengthening the company's foundation and executing its core strategy, while potentially expanding access to capital and improving market visibility.\n\nThe company is a regenerative medicine firm focused on perinatal tissue allograft products, utilizing proprietary processing technologies such as BioRetain, CryoTek, and SteriTek.","key_figures":null,"named_entities":{"people":[{"name":"Jason Matuszewski","role":"Chairman and CEO"},{"name":"Philip Trip Taylor","role":"Investor Relations Contact"},{"name":"Jennifer Horton","role":"Public Relations Contact"}],"products":["BioRetain","CryoTek","SteriTek","Neox","Clarix","VENDAJE","American Amnion"],"companies":[{"name":"BioStem Technologies, Inc.","ticker":"BSEM"},{"name":"The Nasdaq Stock Market LLC","relationship":"exchange"},{"name":"American Association of Tissue Banks","relationship":"accreditation body"},{"name":"Gilmartin","relationship":"investor relations firm"},{"name":"Relevance","relationship":"public relations firm"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-08-07T09:30:07.143Z","global_importance":15,"audience_relevance":15,"importance_components":{"tickerTier":"micro-cap","eventGravity":"exchange-uplisting"}},"durationMs":133561,"modelName":"glm-4.7"}}